| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $0 | 0 | 0 |
Sells | $113,591 | 10 | 100 |
| Ophir Eran | President and CEO | 0 | $0 | 3 | $42,934 | $-42,934 |
| Levine Zurit | SVP, Business Development | 0 | $0 | 7 | $70,657 | $-70,657 |
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Over the last 12 months, insiders at Compugen Ltd. have bought $0 and sold $113,591 worth of Compugen Ltd. stock.
On average, over the past 5 years, insiders at Compugen Ltd. have bought $0 and sold $113,591 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-04-24 | Sale | Levine Zurit | SVP, Business Development | 2,000 0.0022% | $3.20 | $6,400 | -12.10% | |
| 2026-04-24 | Sale | Ophir Eran | President and CEO | 5,000 0.0055% | $3.20 | $16,001 | -12.10% | |
| 2026-04-14 | Sale | Levine Zurit | SVP, Business Development | 2,000 0.0024% | $2.80 | $5,600 | -4.17% | |
| 2026-04-14 | Sale | Ophir Eran | President and CEO | 5,000 0.0062% | $2.90 | $14,521 | -4.17% | |
| 2026-04-10 | Sale | Levine Zurit | SVP, Business Development | 3,125 0.0034% | $2.56 | $8,013 | +6.98% | |
| 2026-04-08 | Sale | Levine Zurit | SVP, Business Development | 5,375 0.0059% | $2.42 | $13,008 | +20.52% | |
| 2026-04-07 | Sale | Levine Zurit | SVP, Business Development | 2,500 0.0026% | $2.30 | $5,750 | +18.97% | |
| 2026-04-01 | Sale | Levine Zurit | SVP, Business Development | 3,500 0.0037% | $2.20 | $7,700 | +25.23% | |
| 2026-04-01 | Sale | Ophir Eran | President and CEO | 5,625 0.006% | $2.21 | $12,413 | +25.23% | |
| 2026-03-26 | Sale | Levine Zurit | SVP, Business Development | 11,875 0.0124% | $2.04 | $24,187 | +32.28% |
| Increased Positions | 23 | +26.14% | 2M | +16.57% |
| Decreased Positions | 28 | -31.82% | 2M | -15.51% |
| New Positions | 12 | New | 2M | New |
| Sold Out Positions | 11 | Sold Out | 1M | Sold Out |
| Total Postitions | 83 | -5.68% | 13M | +1.06% |